|2.65 0 (0%)||11-29 11:29|
|Targets||6-month :||3.34||1-year :||3.9|
|Resists||First :||2.85||Second :||3.34|
|Supports||First :||2.22||Second :||1.83|
|MAs||MA(5) :||2.7||MA(20) :||2.4|
|MA(100) :||2.19||MA(250) :||3.48|
|MACD||MACD :||0.1||Signal :||0|
|%K %D||K(14,3) :||78.8||D(3) :||83.6|
|52-week||High :||8.81||Low :||1.53|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PSTX ] has closed below upper band by 26.1%. Bollinger Bands are 33.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||2.71 - 2.73||2.73 - 2.74|
|Low:||2.56 - 2.57||2.57 - 2.59|
|Close:||2.62 - 2.65||2.65 - 2.68|
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||95 (M)|
|Shares Float||54 (M)|
|Held by Insiders||28.2 (%)|
|Held by Institutions||52.3 (%)|
|Shares Short||3,030 (K)|
|Shares Short P.Month||3,910 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.28|
|Profit Margin||-264.1 %|
|Operating Margin||-387.4 %|
|Return on Assets (ttm)||-25.1 %|
|Return on Equity (ttm)||-77.4 %|
|Qtrly Rev. Growth||-92 %|
|Gross Profit (p.s.)||-0.24|
|Sales Per Share||0.52|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-61 (M)|
|Levered Free Cash Flow||-4 (M)|
|Price to Book value||2.07|
|Price to Sales||5.12|
|Price to Cash Flow||-4.18|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|